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Abstract 59	  
Glucocorticoids (GCs) exert their effects through regulation of gene expression after activation in the cytoplasm of the 60	  
glucocorticoid receptor (GR) encoded by NR3C1 gene. A negative feedback mechanism resulting in GR autoregulation 61	  
has been demonstrated, through the binding of the activated receptor to intragenic sequences called GRE-like elements, 62	  
contained in GR gene.  63	  
The long noncoding RNA growth arrest–specific transcript 5 (GAS5) interacts with the activated GR suppressing its 64	  
transcriptional activity. The aim of this study was to evaluate the possible role of GAS5 and NR3C1 gene expression in 65	  
the anti-proliferative effect of methylprednisolone in peripheral blood mononuclear cells and to correlate the expression 66	  
with the individual sensitivity to GCs. Subjects poor responders to GCs presented higher levels of GAS5 and NR3C1 in 67	  
comparison with good responders. We suggest that abnormal levels of GAS5 may alter GC effectiveness, probably 68	  
interfering with the mechanism of GR autoregulation.  69	  
 70	  
Introduction 71	  
Glucocorticoids (GCs), in particular prednisone and methylprednisolone (MP) are commonly used in inflammatory and 72	  
autoimmune disorders and in the treatment of leukaemia and lymphomas, and in the prevention of rejection in 73	  
transplant patients [1, 2]; however considerable inter-individual differences in their efficacy and side effects have been 74	  
reported [3, 4]. The mechanisms involved in GC resistance are scarcely understood and there is presently no means to 75	  
predict the response in advance [5-7].  76	  
GCs exert their effects on target cells primarily through the regulation of gene expression after activation in the 77	  
cytoplasm of the glucocorticoid receptor (GR), which acts as a transcription factor [8, 9]. The biological and molecular 78	  
mechanisms involved in GR activity have been studied in details, but to date GR expression pattern does not represent a 79	  
reliable predictive tool to explain the complex mechanism of GC resistance observed in clinical practice. The GR, 80	  
encoded by NR3C1 gene, presents a C-terminal ligand-binding domain (LBD), an N-terminal transcriptional regulatory 81	  
region, and a central DNA binding domain (DBD) [10, 11]. Upon ligand binding, the receptor transmigrates to the 82	  
nucleus and binds to glucocorticoid responsive elements (GREs), palindromic DNA-binding sites in the promoter 83	  
region of target genes, assembling a transcriptional activation complex, and inducing or repressing gene expression [12-84	  
14].  85	  
It has been shown that GR expression is regulated by the receptor itself after prolonged GC treatment: in 1986 Okret et 86	  
al. observed a negative feedback mechanism enabling cells to attenuate the continuous signal evoked by chronic 87	  
exposure to the ligand, resulting in GR downregulation, through the binding of the activated receptor to intragenic 88	  
sequences called GRE-like elements (GREs-like), contained in the GR gene [15-17]. These observations have been 89	  
subsequently confirmed by other authors [16, 17]. 90	  
It was recently demonstrated that growth arrest–specific transcript 5 (GAS5), a long noncoding RNA (lncRNA), 91	  
interacts with the activated GR, preventing its association with GREs, and consequently suppressing its transcriptional 92	  
activity [18]. This interaction is physiologically relevant as it occurs at concentrations of the GR ligand dexamethasone 93	  
at 10−10 M, that area lower than that of physiological endogenous glucocorticoid, cortisol. Kino et al.  observed that 94	  
overexpression of GAS5 greatly inhibits the transcription of GR target genes, among which those that encode cellular 95	  
inhibitor of apoptosis 2 (cIAP2) and serum- and glucocorticoid-regulated kinase 1 (SGK1); the reduced binding of the 96	  
GR to the promoters was demonstrated by chromatin immune-precipitation analysis [18, 19].  97	  
The aim of the present investigation was to evaluate the possible role of GAS5 and NR3C1 gene expression in the anti-98	  
proliferative effect of methylprednisolone (MP) in peripheral blood mononuclear cells (PBMCs) obtained from healthy 99	  
subjects and to correlate the expression with the individual sensitivity to GCs. PBMCs can be induced to proliferate in 100	  
vitro using mitogens, and proliferation is inhibited by GCs, although the mechanism is still unclear [20]. It has been 101	  
suggested that the in vitro test is useful for predicting GC responsiveness in rheumatoid arthritis [21], systemic lupus 102	  
erythematosus [22], bronchial asthma [23], renal transplant rejection  [24] and ulcerative colitis [25].  103	  
The results presented here indicate that abnormal levels of GAS5 may alter GC effectiveness probably interfering with 104	  
the mechanism of GR autoregulation. Our findings provide the basis for further studies, identifying a lncRNA as a 105	  
potential marker	   involved in GC pathway and thus providing a new view upon its implication in the phenomenon of 106	  
drug resistance. 107	  
 108	  
Materials and methods 109	  
Subjects 110	  
Samples from 14 blood donors were collected between January 2013 and October 2013 from the Transfusion Center, 111	  
Azienda Ospedaliera Universitaria, Trieste. Blood was obtained by venipuncture between 08.00 a.m. and 10.00 a.m. to 112	  
minimize the variability due to circadian rhythm, and immediately processed. All donors have signed an individual 113	  
review-board-approved consent for  blood sampling and use for research purposes. Blood samples were delivered to the 114	  
University of Trieste with no individually identifiable information. A total of 9 ml of each buffy coat was used for the 115	  
isolation of PBMCs.   116	  
 117	  
In vitro proliferation assay 118	  
The effect of MP on the proliferation of PBMCs was determined	  as reported by Cuzzoni and colleagues [26]. Nonlinear 119	  
regression of dose–response data was performed using Graph-Pad Prism version 4.00 for computing IC50, the MP 120	  
concentration required to reduce proliferation to 50%. I250ng/ml was also calculated and defined as the inhibition of the 121	  
proliferation achievable at 250 ng/ml concentration of MP. Subjects were divided into two groups based on their 122	  
individual response to MP and considered good or poor responders if their I250ng/ml values were respectively above or 123	  
below the median of the whole population.  124	  
 125	  
Total RNA isolation  126	  
PBMCs were treated with MP at a concentration of 250 ng/ml and after 72 h the cells were collected and preserved in 127	  
RNAlater® solution (Ambion) at -20 °C. RNA extraction using the MagMaxTM-96 Total RNA Isolation Kit (Ambion, 128	  
Applied Biosystems, Foster City, CA) was performed according to the manufacturer’s instructions. The RNA 129	  
concentration and purity were calculated by Nano Drop instrument (NanoDrop 2000, EuroClone®).  130	  
	  131	  
Quantitative real-time PCR (TaqMan®) 132	  
Expression levels of GAS 5 and NR3C1 genes were evaluated by real-time RT-PCR TaqMan® analysis using the 133	  
CFX96 real-time system-C1000 Thermal Cycler (Bio-Rad Laboratories). The reverse transcription reaction was carried 134	  
out with the High Capacity RNA-to-cDNA Kit (Applied Biosystem) and the real-time PCR was performed in triplicate 135	  
using the TaqMan® Gene Expression Assay to assess GAS5 and NR3C1 mRNA expressions, according to the 136	  
manufacturer’s instructions. The thermal cycling conditions for TaqMan assays were as follows: 2 min at 50 °C and 10 137	  
min at 95 °C followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s.  138	  
The expression levels of GAS5 and NR3C1 were evaluated using the comparative Ct method (2-ΔΔCt method) [27]. Ct 139	  
values were corrected based on PCR efficiencies using LinRegPCR [28]. The GAS5 and NR3C1 expression values 140	  
were normalized using the 18S as housekeeping gene.	  	  141	  
 142	  
Western Blotting 143	  
Cells (1x107) were cultured as reported for gene expression analysis, collected, and after washing with cold PBS, lysed 144	  
using a lysis buffer composed by Tris-HCl 10mM pH 7.4, EDTA 100 mM, NaCl 100 mM, SDS 0.1%, Protease 145	  
inhibitor cocktail 1%. Samples were then run in a PAGErTM Mini-gel Chamber (Lonza, Milan, Italy) using a 10% 146	  
acrylamide gels with a Trys-Glycine buffer and subsequently semi-dry blotted for 2 h with 50 mA current on PVDF 147	  
membrane. After blocking for 1 h with 5% not-fat milk in PBS, membranes were incubated overnight at 4 °C with 148	  
primary antibodies (anti-actin 1:20000, Millipore; anti-GRα 1:500, Thermo Scientific, Milan, Italy). Membranes were 149	  
then washed in Tween/Tris buffered salt solution (TTBS) and incubated for 1 h at 37 °C with an anti-rabbit HRP-150	  
conjugated secondary antibody 1:50000 (Millipore, Milan, Italy). Chemiluminescence was developed using LiteAblot® 151	  
TURBO (Euroclone, Milan, Italy) and exposed on Kodak Biomax film. GR protein expression was quantified on 152	  
western blots images using the ImageJ software, version 1.45s and are reported as % with respect to actin. 153	  
DiOC6/PI test 154	  
3,3′-Dihexyloxacarbocyanine (DiOC6) dye (Molecular Probes, Montluçon, France) was used to discriminate viable and 155	  
dying cells with flow cytometer (FACScan, Becton-Dickinson) as marker of decreased mitochondrial transmembrane 156	  
potential (ΔYm). 6 x 105 cells per well were seeded in 24-well plates. MP dissolved in culture media was added (final 157	  
concentration: range from 0.019 ng/ml to 20 µg/ml), and plates were incubated at 37 °C for 72 h. Subsequently, DiOC6 158	  
10 µM was added, and the incubation continued for 20 additional min. Subsequently, the PBMCs, were washed and 0.1 159	  
mg/mL propidium iodide (PI) were added to each sample and incubated for 10 min at room temperature .	  Cells with 160	  
compromised cellular membrane (necrotic and late apoptotic cells) were stained with PI. Flow cytometric 161	  
measurements were analyzed by means of the FlowJo software. 162	  
 163	  
Statistical analyses 164	  
Statistical analyses were performed using the R statistical software (version 2.9.1). The nonparametric Wilcoxon test 165	  
was used for the analysis of gene expression for all subjects and between good and poor responders. Western blot 166	  
results were analyzed using T-test and two-way analysis of variance (two-way ANOVA) was used for the flow 167	  
cytometric analysis using the probes DiOC6 and PI. P-values < 0.05 were considered statistically significant. 168	  
 169	  
Results  170	  
Individual sensitivity to MP 171	  
The effect of MP on concavalin A-induced proliferation was assessed on PBMCs obtained from 14 healthy blood 172	  
donors (mean age 49.5, range 21-57 years; 21.4% female and 78.6% male). Using nonlinear regression for proliferation 173	  
data, a sigmoidal dose-response curve was extrapolated for each subject, and, in accordance with previous papers [29], a 174	  
wide inter-individual variation in IC50 and I250ng/ml was observed (IC50 median value 1.16x10-6 M, range 2.75x10-9 M – 175	  
1.60x10-4 M; I250ng/ml median value 53%, range 14-85.5%). 176	  
Subjects were divided into two groups based on whether their I250ng/ml values were above the median (good responders, 177	  
7 subjects; median 72%, range 75-97%) or below (poor responders, 7 subjects; median 29%, range 14-52%).  178	  
 179	  
GAS5 and NR3C1 pattern during MP treatment in PBMCs 180	  
To evaluate the role of transcriptional response in the variability in GC sensitivity, GAS5 and NR3C1 gene expression 181	  
was evaluated in concanavalin A-stimulated PBMCs treated for 72 h with MP.  182	  
In all the subjects studied, in untreated cells, no differences in GAS5 and NR3C1 expression were observed between 183	  
time 0 and after 72 h in culture (Mann-Whitney test; GAS5 median and range: time 0 1.8 x 10-4 vs 72 h 1.4 x 10-4 p-184	  
value= 0.39; NR3C1 median: time 0 8.5x10-5 vs 72 h 4.2 x 10-5, p-value= 0.16).  185	  
When all subjects were considered, treatment with MP 250 ng/ml for 72 h induced a slight reduction of GAS5 and 186	  
NR3C1 gene expression  (expressed as fold change of MP treated vs untreated controls, GAS5: median -1.45, min -40.9 187	  
max +11.0; NR3C1: median - 1.42, min -11.8 max +9.7).  188	  
The gene expression pattern was evaluated in good and poor responders: in the good response group a downregulation 189	  
of both GAS5 and NR3C1 genes was evident in cells treated for 72 h with MP at 250 ng/ml in comparison with their 190	  
untreated controls, (fold change: GAS5: median - 2.14, min -40.9 max +2.5; NR3C1: median - 5.72, min -11.8 max -191	  
1.2). On the contrary, the poor response group showed an upregulation of the same genes (fold change: GAS5: median 192	  
+ 1.98, min -1.8 max +11.0; NR3C1: median + 2.29, min -2.5 max +9.7). These differences between the two groups 193	  
were statistically significant  (Wilcoxon test; MP good response vs MP poor response: GAS5 p-value=0.011; NR3C1 p-194	  
value=0.017) (Fig.1).  195	  
To confirm the expression of the GR protein, western blot analysis was performed. The quantification, normalized to 196	  
the structural protein actin, was carried out in 2 good and 2 poor responders after treatment with MP for 72 h at 250 197	  
ng/ml, confirming the same pattern observed by gene expression analysis. Indeed, a reduction of GR expression after 198	  
MP treatment was evident in the good response group. In particular, the level of protein expression of the untreated 199	  
controls (76±6 % GR expression with respect to actin) was significantly decreased in cells exposed to 250 ng/ml MP for 200	  
72 h (25±3 %; p<0.001; Fig. 2). On the contrary, in the poor response group, the level of GR was significantly higher in 201	  
treated cells (91±13%) in comparison to untreated controls (68±4%; p < 0.01; Fig. 2).  202	  
 203	  
GAS5 as a modulator of the response to MP   204	  
To exclude that the increase of GAS5, observed in our resistant subjects, was related to the apoptotic state, PBMCs 205	  
were treated with MP for 72 h, stained with DiOC6 and PI and then analyzed by flow cytometric technique. The 206	  
combination of DiOC6-PI allows evaluating mitochondrial depolarization-membrane damage.  207	  
In our experimental conditions, the increase of GAS5 was not related to the apoptotic cell death in PBMCs treated with 208	  
MP, and flow cytometric analysis pointed out that, at 72 h, treatment with MP induced mitochondrial depolarization, 209	  
that was more evident in good responder subjects (Fig. 4, poor vs good responders two-way ANOVA: p<0.05); on the 210	  
contrary, no difference in PI fluorescence signal was evident between treated and untreated cells (data not shown) 211	  
indicating that even high concentrations of MP did not induce cellular membrane damage. 212	  
 213	  
Discussion 214	  
Our results indicate that GAS5 may alter GC effectiveness probably interfering with the mechanism of GR 215	  
autoregulation.  216	  
We hypothesize that upregulation of GAS5, occurring in poor responder PBMCs after treatment with MP, prevents the 217	  
activated GR from binding to intragenic control elements on the NR3C1 gene, thus preventing the transcriptional 218	  
repression of the gene (Fig. 3). Conversely, downregulation of GAS5 occurring in good responders does not hamper the 219	  
binding of the activated receptor to GRE-like sequences (Fig. 3). However, it should be remembered that other 220	  
mechanisms, such as post transcriptional modification, may be involved in the downregulation of the GR [15].	  	  221	  
Our observations strongly suggest that GAS5 could be important in the regulation of the response to GCs. Moreover it 222	  
can be assumed that the altered expression of endogenous GAS5 is a glucocorticoid-mediated event, indeed in untreated 223	  
cells, both of good and poor responders, no differences in GAS5 relative quantification were observed. The mechanisms 224	  
through which this transcriptional modulation occurs is not yet clear; to date it is only known that the expression of 225	  
GAS5 mRNA is regulated at the posttranscriptional level during growth arrest and at the transcriptional level in 226	  
differentiated cells [30].   227	  
GAS5 was reported to act as a sensitizer of apoptosis [31-34]. Our data showed that in resistant subjects, in which 228	  
GAS5 was upregulated, cells proliferation at 250 ng/ml of MP was higher compared to responders and this data was 229	  
confirmed by flow cytometric analysis. Hence, in our experiments, GAS5 could be considered a key mediator of GC 230	  
resistance mechanism in PBMCs as it does not act as a growth arrest–specific transcript. 231	  
 232	  
 233	  
 234	  
Conclusion 235	  
The antiproliferative in vitro effect of GCs has been correlated with clinical response to these agents in various diseases 236	  
[21-25]. Our results suggest that the evaluation of GAS5 and NR3C1 gene expression, integrated with a lymphocyte 237	  
proliferation assay, could lead to the identification of GC resistant subjects. This is the first report about the functional 238	  
effects of changes in GAS5 expression in GC resistance, although the molecular mechanisms involved in this 239	  
phenomenon need further investigations.  240	  
In conclusion, the altered expression of endogenous GAS5 seems to be a GC-mediated event, leading to a different 241	  
regulation of the NR3C1 gene. If these results are confirmed in a larger series and in patients by chronic inflammatory 242	  
and  autoimmune diseases, GAS5 should be considered as a candidate marker of GC resistance.  243	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Fig. 1. Gene expression fold change of NR3C1 (on the left) and GAS5 (on the right) in good and poor responder 352	  
subjects after treatment with MP for 72 h at 250 ng/ml compared to untreated controls. Wilcoxon test * p-value<0.05 353	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Fig. 2. A.) Protein expression of GR evaluated by western blot analysis on PBMCs in good and poor responder subjects 365	  
treated (+) or untreated (-) after 72 h with MP; B.) Percentage of GR expression evaluated in PBMCs in good and poor 366	  
responder subjects treated (grey bars) or untreated (black bars) for 72 h with MP in respect to actin; T-test analysis: MP 367	  
treated cells vs untreated control ** p-value<0.01; *** p-value<0.001. 368	  
 369	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Fig. 3. Potential role of GAS5 in GC response and in the process of autoregulation of the GR. 387	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Fig. 4. Effect of 72 h incubation with MP on PBMCs obtained from two good and poor responder subjects: the 401	  
histograms represent the percentage of inhibition of DiOC6 fluorescence signal; Two way ANOVA: responder vs 402	  
resistant interaction * p-value<0.05. 403	  
 404	  
